DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20213195

Mortality in psoriasis and psoriatic arthritis: systematic review and meta-analysis

Karen Fabiola Velásquez-Hernández, Maria Luisa Peralta-Pedrero, Miriam de Jesús Velásquez-Hernández, Alan Isaac Valderrama-Treviño, Martha Alejandra Morales-Sánchez

Abstract


We had found contradictory results that have been reported in recent publications regarding the mortality risk of patients with psoriasis (Pso) and psoriatic arthritis (PsA). These patients have aggregated risk behaviors, which directly impacted their morbidity/mortality. We included 15 studies, with a total population of that reported mortality risk in Pso and PsA patients. We calculated crude mortality rate (CMR) of each one and pooled CMR by group and 95% confidence intervals (CI). The pooled CMR for Pso was 14/1000 (95% CI: 6-21%), 12/1000 (95% CI: 10-15%) in mild, 19/1000 (95% CI: 15-23%) in severe and 12/1000 was observed (95% CI: 10-14%) in PsA. Mortality was relatively higher in PsA patients when compared with Pso, with a RR of 1.03 (95% CI: 1.01-1.06, p<0.01). Pso was associated with increased mortality when compared to the general population. Mild Pso and PsA have the same increased mortality, then again as the severity of Pso increased, so does its mortality. The final comparative mortality between patients with PsA and those with Pso was around 3%.


Keywords


Psoriasis, Arthritis psoriatic, Mortality, Crude mortality rate

Full Text:

PDF

References


Han JH, Lee JH, Do HK, Seo H, Bang CH, Park YM, et al. Epidemiology and medication trends in patients with psoriasis: a nationwide population-based cohort study from Korea. Acta Derm Venereol. 2018;98(4):396-400.

Sui LM, Yi-Chun Y, Ting CY, Lai M. All-cause and cause-specific mortality in patients with psoriasis in taiwan: a nationwide population-based study. J Invest Dermatol. 2017;137(7):1468-73.

Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the general practice research database. Eur Heart J. 2010;31(8):1000-6.

Chanussot C, Arenas R. Psoriasis, a descriptive study of comorbidities in 114 patients. Dermatologia CMQ. 2015;13(1):20-3.

Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-71.

Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, et al. Mortality in psoriatic arthritis-a single-center study from the UK. J Rheumatol. 2010;37(10):2141-4.

Ogdie A, Maliha S, Shin D, Love TJ, Baker J, Jiang Y, et al. Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. Rheumatology (Oxford). 2017;56(6):907-11.

Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2018;19(1):58.

Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM, Identification and management of psoriasis and associated comorbidity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-85.

Griffiths CEM, Walt JMVD, Ashcroft DM, Flohr C, Naldi L, Nijsten T, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol. 2017;177(1):4-7.

Gupta R, Debbaneh MG, Liao W. Genetic epidemiology of psoriasis. Curr Dermatol Rep. 2014;3(1):61-78.

Egeberg A, Skov L, Gislason GH, Thyssen JP, Mallbris L. Incidence and prevalence of psoriasis in Denmark. Acta Derm Venereol. 2017;97(7):808-12.

Duarte GV, Silva LP, Oliveira MDFPD. Epidemiology and treatment of psoriasis: a Brazilian perspective. Psoriasis (Auckl). 2015;5:55-64.

Langley R, Krueger GG, Griffiths C. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(2):18-23.

Hae JS, Chul JP, Tae YK, Choe YB, Lee S, Kim NI, et al. The clinical profile of patients with psoriasis in korea: a nationwide cross-sectional study (EPI-PSODE). Ann Dermatol. 2017;29(4):462-70.

Noe MH, Shin DB, Wan MT, Gelfand JM. Objective measures of psoriasis severity predict mortality: a prospective population- based cohort study. J Invest Dermatol. 2018;138(1):228-30.

Salahadeen E, Torp-Pedersen C, Gislason G, Hansen PR, Ahlehoff O. Nationwide population-based study of cause-specific death rates in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;29(5):1002-5.

Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012;14(4):343-8.

Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(3):12-29.

Gulliver W. Long-term prognosis in patients with psoriasis. Br Assoc Dermatol. 2008;159(2):2-9.

Stern RS, Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol. 2011;131(5):1159-66.

Pearce DJ, Higgins KB, Stealey KH, Balkrishnan R, Crane MM, Camacho F, et al. Adverse events from systemic therapies for psoriasis are common in clinical practice. J Dermatolog Treat. 2006;17(5):288-93.

Masson W, Rossi E, Galimbe ML, Krauss J, Estrada JN, Galimberti R, et al. Mortality in patients with psoriasis. Analysis of a retrospective cohort. Medicina Clinica Barcelona. 2017;148(11):483-8.

Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol. 2010;163(3):586-92.

Svedbom A, Dalen J, Mamolo C, Cappelleri JC, Mallbris L, Petersson IF, et al. Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study. Acta Derm Venereol. 2015;95(7):809-15.

Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National psoriasis foundation surveys 2003 to 2011. Dermatology. 2012;225(2):121-6.

Ogdie A, Haynes K, Troxel AB, Love TJ, Hennessy S, Choi H, et al. The risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis, and psoriasis: a longitudinal cohort study. Ann Rheum Dis. 2014;73(1):149-53.

Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1332-43.

Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis. Arthritis Rheum. 1997;40(10):1868-72.

Yaser A, Brian DMT, Schentag CT. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum. 2007;56(8):2708-14.

Shbeeb M, Uramoto K, Gibson L, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000;27(5):1247-50.

Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36(2):361-7.

Springate D, Parisi R, Kontopantelis E, Reeves D, Griffiths CEM, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017;176(3):650-8.

Ying-Xiu D, Ming-Chun H, Hsiao-Yun H, Chang Y, Chen T, Li C, et al. The risk of mortality among psoriatic patients with varying severity: a nationwide population-based cohort study in Taiwan. Int J Environ Res Public Health. 2018;15(12):2622.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology. JAMA. 2000;283(15):2008-12.

Wells G, Shea B, Connel D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quailty of nonrandomised studies in meta-analyses. Ottawa Hosp. 2009.

Moola S, Munn Z, Tufanaru C. Chapter 7: Systematic reviews of etiology and risk. Joanna Briggs Instit Rev Manual. 2017.

GRADEpro Guideline Development Tool. Fact sheet: McMaster University, 2015. Available at: https://gradepro.org/cite/. Accessed on 2 July 2021.

Manouchehrinia A, Tanasescu R, Tench CR, Constantinescu CS. Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. J Neurol Neurosurg Psychiatry. 2016;87(3):324-31.

WHO. Fact sheet: The top 10 causes of death, 2016. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed on 2 July 2021.

Knoema Corporation. Fact sheet: Population estimates and projections, 2017. Available at: https://knoema.com/WBPEP2018Oct/population-estimates-and-projections?country=1000530&series=1000140. Accessed on 2 July 2021.

The world bank. Death rate, crude (per 1,000 people), 2017. Available at: https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?contextual=aggregate. Accessed on 2 July 2021.

Alcañiz M. Demographic changes in global society. Pap Poblac. 2008;14(57).

Bloom DE, Luca DL. The global demography of aging: facts, explanations, future. IZA. 2016.

Gelfand JM, Troxel AB, Lewis JD. The risk of mortality in patients with psoriasis. Archiv Dermatol. 2007;143(12):1493-9.

Skov L, Thomsen SF, Kristensen LE. Cause-specific mortality in patients with psoriasis and psoriatic arthritis. Br J Dermatol. 2019;180:100-7.